GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Precigen Inc (FRA:I5X) » Definitions » Float Percentage Of Total Shares Outstanding

Precigen (FRA:I5X) Float Percentage Of Total Shares Outstanding : 53.82% (As of May. 21, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Precigen Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Precigen's float shares is 135.85 Mil. Precigen's total shares outstanding is 252.42 Mil. Precigen's float percentage of total shares outstanding is 53.82%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Precigen's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Precigen's Institutional Ownership is 12.52%.


Precigen Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Precigen's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=135.85/252.42
=53.82%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Precigen (FRA:I5X) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Precigen Inc (FRA:I5X) » Definitions » Float Percentage Of Total Shares Outstanding
Traded in Other Exchanges
Address
20374 Seneca Meadows Parkway, Germantown, MD, USA, 20876
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.

Precigen (FRA:I5X) Headlines

No Headlines